Balchem Corporation

Balchem Corporation(BCPC)股票分析

$170.730

+0.205 (+0.12%)收盘时

Loading chart…
最高
172.390
开盘
171.160
成交量加权均价
171.02
成交量
197.30K
市值
4.92B
最低
169.950
成交额
33.74M
企业价值/息税折旧摊销前利润(TTM)
18.63

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

AI 分析 of Balchem Corporation (BCPC)

买入

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

估值指标

Balchem Corporation(BCPC)当前预期市盈率为 29.33,5 年平均预期市盈率为 32.65。

预期市盈率

合理
5 年均值 P/E
32.65
当前P/E
29.33
高估
36.01
低估
29.30

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.55
当前EV/EBITDA
18.63
高估
22.64
低估
18.47

预期市销率

合理
5 年均值 P/S
4.78
当前P/S
4.54
高估
5.36
低估
4.20

Alphio AI 对 BCPC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BCPC

$162.17

情景价格

基

基准

基准 · 50%BCPC

$159.96

情景价格

悲

悲观

悲观 · 25%BCPC

$150.29

情景价格

持有 BCPC 的大户

S

Salem Investment Counselors, Inc.

+ 持有BCPC

+4.26%

3个月收益率

W

Wasatch Advisors LP

+ 持有BCPC

-0.86%

3个月收益率

N

Nationwide Fund Advisors

+ 持有BCPC

-1.49%

3个月收益率

事件时间线

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

资讯

BCPC 常见问题 —— 由 Alphio AI 解答

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易